<DOC>
	<DOCNO>NCT00133887</DOCNO>
	<brief_summary>In population kidney transplant recipient develop first squamous cell carcinoma , aim study assess incidence subsequent skin cancer 2 year patient switch rapamycin compare patient maintain calcineurin inhibitor .</brief_summary>
	<brief_title>TUMORAPA 1 : Efficacy Rapamycin Secondary Prevention Skin Cancers Kidney Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Skin Neoplasms</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Calcineurin Inhibitors</mesh_term>
	<criteria>First posttransplant squamous cell carcinoma kidney transplant recipient calcineurin inhibitor Other squamous cell carcinoma past history More 2 transplantation Patients calcineurin inhibitor Unstable graft function Non control hyperlipidemia ( cholesterol &gt; 7.8 mmol/l triglyceride &gt; 3.95 mmol/l ) Leucopenia &lt; 3000/mm3 Thrombocytopenia &lt; 100,000/mm3 Liver dysfunction Pregnancy Allergy macrolides</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Squamous cell carcinoma</keyword>
	<keyword>kidney transplant recipient</keyword>
	<keyword>rapamycin</keyword>
	<keyword>Skin cancer kidney transplant recipient</keyword>
</DOC>